amifostine anhydrous has been researched along with Leukemia in 11 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Human lymphocytes, p53 protein-deficient acute promyelocytic leukemia cell line HL-60, murine pro-B lymphoid cell line BaF3 and its TEL/ABL-transformed clone cells were exposed to idarubicin with and without pre-treatment with amifostine." | 3.71 | Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells. ( Błasiak, J; Drzewoski, J; Gloc, E; Młynarski, W; Skórski, T, 2002) |
| " The results of this study will show that amifostine protects normal late and early progenitor cells for the toxic effects of cyclophosphamide derivatives while preserving their antileukaemic effects." | 1.29 | Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects. ( Douay, L; Giarratana, MC; Gorin, NC; Hu, C, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pinto, JL | 1 |
| Fonseca, FL | 1 |
| Marsicano, SR | 1 |
| Delgado, PO | 1 |
| Sant'anna, AV | 1 |
| Coelho, PG | 1 |
| Maeda, P | 1 |
| Del Giglio, A | 1 |
| Gloc, E | 2 |
| Warszawski, M | 1 |
| Młynarski, W | 2 |
| Stolarska, M | 1 |
| Hoser, G | 1 |
| Skorski, T | 2 |
| Błasiak, J | 2 |
| Drzewoski, J | 1 |
| Facorro, G | 1 |
| Sarrasague, MM | 1 |
| Torti, H | 1 |
| Hager, A | 1 |
| Avalos, JS | 1 |
| Foncuberta, M | 1 |
| Kusminsky, G | 1 |
| Douay, L | 3 |
| Hu, C | 3 |
| Giarratana, MC | 3 |
| Gorin, NC | 4 |
| Bouchet, S | 1 |
| Conlon, J | 1 |
| Capizzi, RL | 2 |
| List, AF | 1 |
| Fauth, F | 1 |
| Martin, H | 1 |
| Sonnhoff, S | 1 |
| Bialleck, H | 1 |
| Wiesneth, M | 1 |
| Mihanovic, B | 1 |
| Hoelzer, D | 1 |
3 reviews available for amifostine anhydrous and Leukemia
| Article | Year |
|---|---|
The potential role of amifostine (Ethyol) in haematological malignancies.
Topics: Acute Disease; Adult; Amifostine; Antineoplastic Agents; Bone Marrow Purging; Bone Marrow Transplant | 1996 |
Clinical status and optimal use of amifostine.
Topics: Amifostine; Animals; Antineoplastic Agents; Bone Marrow Cells; Clinical Trials, Phase III as Topic; | 1999 |
Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia.
Topics: Acute Disease; Amifostine; Animals; Apoptosis; Cytoprotection; Hematologic Neoplasms; Hematopoietic | 1999 |
2 trials available for amifostine anhydrous and Leukemia
| Article | Year |
|---|---|
Systemic chemotherapy-induced microsatellite instability in the mononuclear cell fraction of women with breast cancer can be reproduced in vitro and abrogated by amifostine.
Topics: Amifostine; Antimutagenic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Line, Tu | 2010 |
Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
Topics: Acute Disease; Adjuvants, Immunologic; Adult; Amifostine; Bone Marrow; Bone Marrow Purging; Cyclopho | 2000 |
6 other studies available for amifostine anhydrous and Leukemia
| Article | Year |
|---|---|
TEL/JAK2 tyrosine kinase inhibits DNA repair in the presence of amifostine.
Topics: Amifostine; Animals; Comet Assay; DNA Damage; DNA Repair; Kinetics; Leukemia; Mice; Oncogene Protein | 2002 |
Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells.
Topics: Amifostine; Animals; Cell Line, Transformed; Cell Survival; Comet Assay; DNA Damage; Dose-Response R | 2002 |
Oxidative study of patients with total body irradiation: effects of amifostine treatment.
Topics: Adolescent; Adult; Amifostine; Antioxidants; Bone Marrow Transplantation; Child; Erythrocytes; Femal | 2004 |
Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects.
Topics: Amifostine; Antineoplastic Agents; Bone Marrow Purging; Bone Marrow Transplantation; Cyclophosphamid | 1995 |
Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Topics: Amifostine; Antineoplastic Agents; Bone Marrow; Bone Marrow Purging; Bone Marrow Transplantation; Ce | 1995 |
Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants.
Topics: Amifostine; Bone Marrow Purging; Bone Marrow Transplantation; Cell Separation; Cell Survival; Cultur | 1994 |